Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements

JAMA

Volumn 277, Issue 18, 1997, Pages 1452-1455

  Catalona, William J ^a   Smith, Deborah S ^a   Ornstein, David K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0030913316     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.18.1452     Document Type: Article

References (22)

1. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-1449.
2. Stenman UH, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with alpha-1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594-1598.
3. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273:289-294.
4. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309-1315.
5. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
6. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
7. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer. J Urol. 1994;151:1283-1290.
8. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. Cancer Res. 1991;51:222-226.
9. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 1991;37:1618-1625.
10. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-105.
11. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-1220.
12. Bangma CH, Kranse R, Blijenberg BG, Schroeder FH. The value of screening tests in the detection of prostate cancer, I: results of a retrospective evaluation of 1726 men. Urology. 1995;46:773-778.
13. Luderer AA, Chen Y-T, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995; 46:187-194.
14. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate-specific antigen based screening. J Urol. 1994;152:1732-1736.
15. Smith DS, Bullock AD, Catalona WJ, Herschman JD. Racial differences in a prostate cancer screening study. J Urol. 1996;156:1366-1369.
16. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991; 145:984-987.
17. Benson MC, Whang IS, Pantuck A, et al. Prostate-specific antigen density. J Urol. 1992;147:815-816.
18. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989:89.
19. Colberg JW, Smith DS, Catalona WJ. Prevalence and pathologic extent of prostate cancer in men with prostate-specific antigen levels of 2.9 to 4.0 ng/mL. J Urol. 1993;149:507-509.
20. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
21. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335:304-310.
22. Wingo PA, Bolden S, Tong T, et al. Cancer statistics for African-Americans, 1996. CA Cancer J Clin. 1996;46:113.